Research graph
References from Anafilaxia idiopática recurrente tratada con omalizumab. Local targets link to admitted publications; unresolved targets remain external evidence.
Urticaria crónica espontánea
10.1016/j.medcli.2013.07.022 · 2014 · External reference
Promising option in the prevention of idiopathic anaphylaxis: Omalizumab
10.1111/j.1346-8138.2012.01520.x · 2012 · External reference
Off-label uses of omalizumab
10.1007/s12016-015-8490-y · 2016 · External reference
Idiopathic anaphylaxis successfully treated with omalizumab
10.1016/s1081-1206(10)60296-7 · 2008 · External reference
Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy
10.5415/apallergy.2014.4.2.126 · 2014 · External reference
Omalizumab in idiopathic anaphylaxis
10.1016/s1081-1206(10)60091-9 · 2009 · External reference
Successful treatment of idiopathic anaphylaxis in an adolescent
10.1016/j.jaci.2010.05.043 · 2010 · External reference
Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis
10.2340/00015555-1687 · 2014 · External reference
Omalizumab's role in the treatment of steroid dependent malignant idiopathic anaphylaxis
10.5152/turkpediatriars.2017.2262 · 2017 · External reference
Patologías mediadas por la inmunoglobulina E: de la inmunoglobulina E al omalizumab
10.1016/j.inmuno.2012.08.001 · 2012 · External reference
Omalizumab: mecanismo de acción y desarrollo clínico
2015 · External reference
